Professor Hugh Barrett
Crawley (Australia)
Evolocumab lowers plasma Lp(a) concentration by two kinetic modes of action: From the FLOREY Study
Event: ESC Congress 2017
Topic: Lipids
Session: Lipid metabolism
ESC 365 is supported by
